StemEdit hiPSC CIITA KO RPC-LLF-34-F3
RCRP051
Brand: StemEdit
Human iPSCs with a knockout of both copies of the CIITA gene.
| Product name | Catalog number | Pack size | Price | Price | Price (USD) | Price (GBP) | Price (EUR) |
|---|---|---|---|---|---|---|---|
| StemEdit hiPSC CIITA KO RPC-LLF-34-F3 | RCRP051 | 1 × 10⁶ cells | Ask us | $ 7,500 | £ Ask us | € Ask us |
Note: prices shown do not include shipping and handling charges.
Product Information
Recommended Products
- iMatrix-511 Stem Cell Culture Substrate NP892-011 / NP892-012
- NutriFreez™ D10 Cryopreservation Medium 01-0020-50
- NutriStem™ hPSC XF Culture Medium for Human iPS and ES Cells 01-0005 / 01-0005-100
Ready-to-use Research-Grade HLA Class II knockout iPSCs made using REPROCELL’s RNA Reprogramming Technology.
These cells feature all the advantages of our RNA reprogramming technology, including no retention of reprogramming factors and easy culture in NutriStem hPSC XF Medium. They have been engineered using OpenCRISPR-1 to contain a CIITA (HLA Class II) knockout mutation, which is carefully characterized and offers significant time savings compared to creating your own reprogrammed and edited cell lines.
Explore our other StemEdit Research iPSCs.
The parent line, StemRNA Clinical iPSC Clone LLF-34-F3, is also available for clinical and research use. Please contact us for more info: info-us@reprocell.com.
Table: Characteristics of StemEdit hiPSC CIITA KO RPC-LLF-34-F3 Cells
| Cat. No.: | RCRP051 |
| Parent Strain ID | StemRNA Clinical iPSC Clone LLF-34-F3 |
| Donor Race: | Caucasian |
| Donor Sex: | Female |
| Donor Age: | 22 |
| Reprogramming Technology: | StemRNA Reprogramming Technology |
| Tissue Source: | Skin (Fibroblasts) |
| Karyotype: | Normal (46 XX) |
| Microbiology: | Negative for bacteria, virus, mycoplasma |
Figure: Immunofluorescence staining (Figure) and flow cytometry analysis (Table) for Pluripotency Markers
|
Marker |
Flow Positive Cells |
|
OCT4 |
91.8% |
|
Nanog |
85.4% |
|
SSEA4 |
99.7% |
|
SSEA1 (neg control) |
1.0% |
The Role of B2M and CIITA.
In humans, the B2M protein is required for the presentation of HLA proteins A-G on the cell surface. Disruption of the B2M gene reduces T-cell activation and interferes with the T-cell-mediated immune response through inhibition of Class I HLA signaling. CIITA regulates the expression of the HLA Class II complex. Knocking out CIITA leads to reduced activity of HLA Class II and suppression of the immune response.
Stemgent and the StemEdit brand name are trademarks of REPROCELL Inc., Japan.